Key result
Cognitive impairment affects ~64% of heart failure and ischemic heart disease patients, tracking with LVEF.
Why the study?
Cardiovascular disease and heart failure are recognized contributors to late-life cognitive decline, but data describing domain-specific cognitive profiles and psychiatric symptom burden in Indian cardiac cohorts were limited.
Cross-Sectional (n=86)
No
In an Indian cohort of patients with ischemic heart disease and heart failure, cognitive impairment—particularly in attention and memory—was highly prevalent and strongly correlated with lower LVEF and worse NYHA functional class, highlighting the need for integrated neuropsychiatric screening in cardiac care.
Answers are grounded in this paper and cite their sources.
Cognitive screening may merit evaluation in ischemic heart disease and heart failure; leaves open whether LVEF modification affects cognition.
Background: Cardiovascular disease and heart failure are increasingly recognized contributors to late-life cognitive decline. However, data describing domain-specific cognitive profiles and psychiatric symptom burden in Indian cardiac cohorts remain limited. Materials and Methods: In a cross-sectional study of 86 adults aged ≥40 years with documented myocardial infarction and/or established heart failure, the participants were assessed using Addenbrooke’s Cognitive Examination-III (ACE-III). Depressive and anxiety symptoms were assessed using the Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A). Clinical variables included left ventricular ejection fraction (LVEF), NYHA functional class, cardiac diagnosis, illness duration, vascular comorbidities, and intervention history. Group comparisons used the Chi-square and t -test/Mann–Whitney tests. Associations were assessed using Spearman correlation and regression analysis. Results: Cognitive impairment was highly prevalent: 55/86 (64.0%) scored below ACE-III dementia-range screening cutoffs (indicative of possible cognitive impairment), and 17/86 (19.8%) had mild cognitive impairment; mean ACE-III = 75.15 (SD 13.47). Attention and memory domains were most affected, with strong inter-domain correlations. LVEF correlated positively with ACE-III Total (rho ≈ 0.73, P ≈ 0.001), while NYHA class and age correlated negatively (NYHA vs ACE-III rho ≈ −0.747, P < 0.001). Longer disease duration and greater symptomatic severity were observed to be cross-sectionally associated with worse cognition. Depressive and anxiety symptoms were common across groups. Conclusion: In this single-center sample, lower LVEF, higher NYHA class, and longer cardiac disease duration were associated with marked cognitive dysfunction, especially in attention and memory, supporting a heart–brain nexus and the need for integrated cardiac/neuropsychiatric care.
No takes yet. Share an insight, caveat, or question.
Shiddapur et al. (2026) conducted a cross-sectional in Ischemic heart disease (documented myocardial infarction) and/or established heart failure (n=86). Lower LVEF, higher NYHA functional class, and longer cardiac disease duration was evaluated on Cognitive impairment below Addenbrooke’s Cognitive Examination-III (ACE-III) dementia-range screening cutoffs (rho ≈ 0.73 (LVEF vs ACE-III Total), p=≈ 0.001). Cognitive impairment affected 64.0% (55/86) of ischemic heart disease and heart failure patients, with ACE-III scores correlating positively with LVEF.
Synapse has enriched 10 related papers. Consider them for comparative context: